search
Back to results

A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers

Primary Purpose

Acne Vulgaris

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Topical Gel Vehicle
8% NVN1000 Topical Gel
8% NVN1000 Topical Gel and moisturizer
Sponsored by
Novan, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acne Vulgaris focused on measuring acne

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy Male and Females > 18 years of age
  • High degree of fluorescence of facial skin under Wood's lamp

Exclusion Criteria:

  • Acute or chronic skin disorders
  • Topical or systemic antibiotics within 4 weeks of study enrollment
  • Use of medication that increases risk of methemoglobinemia or influences P. acnes counts
  • Subjects with medical illnesses, anemia, elevated methemoglobin
  • Women who are pregnant, nursing or planning a pregnancy

Sites / Locations

  • KGL, Inc

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Active Comparator

Active Comparator

Arm Label

Topical Gel Vehicle

8% NVN1000 Topical Gel

8% NVN1000 Topical Gel and moisturizer

Arm Description

Once daily application of topical gel vehicle to forehead for 3 days

Once daily application of 8% NVN1000 Topical Gel to the forehead for 3 days

Once daily application of 8% NVN1000 Topical Gel to the forehead, followed 15 minutes later by application of a commercially available moisturizer

Outcomes

Primary Outcome Measures

Cutaneous tolerability
Tolerability based on a four point scale (0-3) for erythema, scaling ,dryness, pruritus, and burning/stinging.

Secondary Outcome Measures

Safety comparison
Assess safety through the comparison of adverse events between groups (lab assessments, physical exams and vital signs).

Full Information

First Posted
December 18, 2012
Last Updated
September 9, 2019
Sponsor
Novan, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01755247
Brief Title
A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers
Official Title
A Phase One, Single-Center, Open-Label, Randomized, Parallel Group, 3 Day Study Evaluating the Safety and Cutaneous Tolerability of NVN10000 Topical Gel in Healthy Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
May 2019
Overall Recruitment Status
Completed
Study Start Date
November 2012 (undefined)
Primary Completion Date
November 2012 (Actual)
Study Completion Date
December 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novan, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
A Phase I, Single-Center, Open-Label, Randomized, Parallel Group, 3 Day Study Evaluating the Safety and Cutaneous Tolerability of NVN1000 Topical Gel in Healthy Volunteers
Detailed Description
This is a 3 day study to assess safety and tolerability of a new topical gel product, NVN1000 with and without the application of a commercially available moisturizer in approximately 15 healthy subjects. The test product will be applied to the forehead of healthy volunteers once daily for 3 days. One group of subjects will have a moisturizer applied to the same area 15 minutes after the test gel was applied and one group of subjects will be treated with the gel vehicle which does not contain the active product. The hypothesis is that the application of moisturizer will not effect safety or local tolerability.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acne Vulgaris
Keywords
acne

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Topical Gel Vehicle
Arm Type
Placebo Comparator
Arm Description
Once daily application of topical gel vehicle to forehead for 3 days
Arm Title
8% NVN1000 Topical Gel
Arm Type
Active Comparator
Arm Description
Once daily application of 8% NVN1000 Topical Gel to the forehead for 3 days
Arm Title
8% NVN1000 Topical Gel and moisturizer
Arm Type
Active Comparator
Arm Description
Once daily application of 8% NVN1000 Topical Gel to the forehead, followed 15 minutes later by application of a commercially available moisturizer
Intervention Type
Drug
Intervention Name(s)
Topical Gel Vehicle
Other Intervention Name(s)
Vehicle
Intervention Type
Drug
Intervention Name(s)
8% NVN1000 Topical Gel
Other Intervention Name(s)
NVN1000 Topical Gel
Intervention Type
Drug
Intervention Name(s)
8% NVN1000 Topical Gel and moisturizer
Other Intervention Name(s)
NVN1000 plus moisturizer
Primary Outcome Measure Information:
Title
Cutaneous tolerability
Description
Tolerability based on a four point scale (0-3) for erythema, scaling ,dryness, pruritus, and burning/stinging.
Time Frame
3 days
Secondary Outcome Measure Information:
Title
Safety comparison
Description
Assess safety through the comparison of adverse events between groups (lab assessments, physical exams and vital signs).
Time Frame
3 Days
Other Pre-specified Outcome Measures:
Title
Propionibacterium acnes counts
Description
P. acnes counts will be obtained at Baseline, Day 1, and Day 3. The change in P acnes counts over time by treatment group will be assessed.
Time Frame
3 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy Male and Females > 18 years of age High degree of fluorescence of facial skin under Wood's lamp Exclusion Criteria: Acute or chronic skin disorders Topical or systemic antibiotics within 4 weeks of study enrollment Use of medication that increases risk of methemoglobinemia or influences P. acnes counts Subjects with medical illnesses, anemia, elevated methemoglobin Women who are pregnant, nursing or planning a pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James J Leyden
Organizational Affiliation
KGL, Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
KGL, Inc
City
Broomall
State/Province
Pennsylvania
ZIP/Postal Code
19008
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers

We'll reach out to this number within 24 hrs